Cargando…
Impact of angiotensin receptor–neprilysin inhibition on vascular function in heart failure with reduced ejection fraction: A pilot study
The mechanisms for the benefits of Angiotensin Receptor Neprilysin Inhibition (ARNi) in heart failure patients with reduced ejection fraction (HFrEF) are likely beyond blood pressure reduction. Measures of vascular function such as arterial stiffness and endothelial function are strong prognostic ma...
Autores principales: | Nathaniel, Sangeetha, McGinty, Shane, Witman, Melissa A. H., Edwards, David G., Farquhar, William B., Hosmane, Vinay, Wenner, Megan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897740/ https://www.ncbi.nlm.nih.gov/pubmed/35246960 http://dx.doi.org/10.14814/phy2.15209 |
Ejemplares similares
-
Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
por: Malik, Jahanzeb, et al.
Publicado: (2021) -
Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
por: Park, Su Yeong, et al.
Publicado: (2023) -
Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction
por: Grant, Andrew D.M., et al.
Publicado: (2020) -
Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40%
por: Zhao, Mingyue, et al.
Publicado: (2019) -
Long-Term Effects of Angiotensin Receptor–Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction
por: Poglajen, Gregor, et al.
Publicado: (2020)